earnings
confidence high
sentiment positive
materiality 0.85
TG Therapeutics Q1 BRIUMVI sales $119.7M (+137% YoY); raises FY revenue guidance
TG THERAPEUTICS, INC.
2025-Q1 EPS reported
$0.03
revenue$120,856,000
- Q1 2025 BRIUMVI U.S. net revenue $119.7M vs $50.5M YoY, up ~137%.
- Net income $5.1M vs net loss $10.7M in Q1 2024; GAAP improvement.
- Raises FY2025 BRIUMVI U.S. net revenue target to ~$560M (prior $525M).
- Raises FY2025 total global revenue target to ~$575M (prior $540M).
- Q2 2025 BRIUMVI U.S. net revenue target set at $135M.